# A Study of Merestinib (LY2801653) in Japanese Participants With Advanced or Metastatic Cancer

> **NCT03027284** · PHASE1 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 19 (actual)

## Conditions studied

- Advanced Cancer
- Metastatic Cancer
- Biliary Tract Carcinoma
- Cholangiocarcinoma
- Gall Bladder Carcinoma
- Solid Tumor
- Non-Hodgkin's Lymphoma

## Interventions

- **DRUG:** Merestinib
- **DRUG:** Cisplatin
- **DRUG:** Gemcitabine

## Key facts

- **NCT ID:** NCT03027284
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-02-03
- **Primary completion:** 2019-06-20
- **Final completion:** 2020-03-17
- **Target enrollment:** 19 (ACTUAL)
- **Last updated:** 2020-05-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03027284

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03027284, "A Study of Merestinib (LY2801653) in Japanese Participants With Advanced or Metastatic Cancer". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT03027284. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*